Exact Sciences (EXAS) Outpaces Medical Peers with 17.8% YTD Return
ByAinvest
Monday, Nov 10, 2025 11:50 am ET1min read
EXAS--
Exact Sciences (EXAS) stock has outperformed its Medical peers this year with a 17.8% return. The company's Zacks Rank is #1 (Strong Buy) and its full-year earnings estimate has increased 47.8%. EXAS belongs to the Medical - Biomedical and Genetics industry, which has gained 11.7% year-to-date. Amylyx Pharmaceuticals (AMLX) is another Medical stock that has outperformed the sector with a 225.7% return.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet